Key Takeaways
- Core B2B steady, consumer drags: Excluding the loss-making institutional and B2C business, core EBITDA grew 12% YoY with a ~16% margin, while the consolidated margin fell to 12.5% as the consumer vertical lost ~₹7 crore.
- Production shutdowns clipped exports: Intermittent 10-12 day plant closures for new reactor installation disrupted production, causing missed export dispatches across all geographies and a QoQ revenue dip of ₹25-30 crore in the core business.
- FY26 is a building year, payoff from FY27: Management framed the year as one of consolidation and capability building, with capacity expansion projects expected to deliver 3x-4x asset turnover and margin expansion only from FY27 onwards.
- Reliance EO delay is manageable for now: Enhanced ethylene oxide supply from Reliance is pushed to Sep-Oct 2026, but soft domestic EO demand means Rossari can currently source more than normal, bridging the gap until its own capacity ramps up.
- What to watch next quarter: Whether the lost export volumes are actually fulfilled in Q2, the pace of loss reduction in the institutional business, and any raw material price pass-through that pressures margins.
Core Operations vs. Consumer Drag
- B2B engine intact: Core operations (excluding institutional and B2C verticals) delivered EBITDA of ₹75 crore, up 12% YoY, with an adjusted margin of about 16%. Volume growth in the B2B business was 11% YoY, matching top-line growth.
- Consumer vertical bleeds: The institutional and B2C business posted a loss of approximately ₹7 crore in Q1, dragging consolidated EBITDA margin down to 12.5% from 13.3% YoY. This vertical, with an annual run rate of ~₹300 crore, is now a significant enough portion of sales to materially weigh on consolidated margins.
- Institutional Cleaning softness: Revenues were soft this quarter on the institutional side, with some orders phased for fulfillment over specific months. Management urged a longer-term view, noting optimism for healthy annual growth over last year's ₹300 crore base.
- Unitop margin erosion: Unitop Chemicals saw gross margin fall from 22% to 18% and EBITDA margin slip from double-digit to high single-digit, even as revenue grew a healthy 18%. Management declined to provide subsidiary-level EBITDA margins, citing transfer pricing movements.
- B2C breakeven target: Management aims to substantially reduce losses by end of this year; if the next two quarters go well, the business could break even this year, and definitely by next year at the EBITDA level.
Ketan Sablok: "We will be holding on to the margin this year. I thought we will drive some operating leverage, right? The employee cost is largely done, and we are cutting losses in the institutional."
Production Disruption & Export Miss
- CAPEX-linked shutdowns: Installation of new reactors required shutting certain production operations for 10-12 days intermittently due to hot work and erection activities, reducing output. EO-related facility safety protocols also mandated production cuts.
- Exports hit across the board: The production loss meant planned export orders could not be dispatched, causing a decline across all geographies because product availability simply was not there. Management expects these lost volumes to be fulfilled in Q2.
- Textile steady despite logistics: Textile chemicals volumes increased YoY, but value-wise some export shipments were delayed due to logistics (bills of lading not received), causing a negative 5-7% impact. Overall textile production in the industry was flat for Q1, and Rossari held its ground.
- Export run rate expectation: On an annualized basis, exports are expected to be around 27-28% of overall turnover.
Capacity Expansion & the EO Timeline
- Three-way expansion underway: Capacity projects across Rossari Biotech, Unitop Chemicals, and Tristar Intermediates are progressing, with phased commissioning expected over coming quarters. Once at optimal utilization, these facilities are expected to deliver 3x-4x asset turnover, driving operating leverage and margin expansion particularly from FY27 onwards.
- Reliance EO delayed, but not a crisis: Reliance's enhanced EO capacity is now expected only by September-October 2026, a delay of a few more quarters. However, softness in all-India EO consumption means Rossari is currently able to source more EO than normal, and management does not foresee a big issue in the next four quarters.
- No firm commitment from Reliance: Management confirmed there is no firm supply commitment from Reliance, only an indication that enhanced capacity should come on stream in the second or third quarter of next year.
- Ramp-up will be gradual: The company will not be able to use 100% of capacity in the first few quarters; ramping up will take time. Good capacity utilization is expected in FY28, with 3-4 years to reach 100%. By the time Rossari ramps up next year, adequate EO should be available.
Sunil Chari: "The Reliance expansion is delayed, and it may take a few more quarters for them to start delivering higher EO. But considering the softness in all India consumption of EO, we are able to get more EO than we were getting normally."
Non-EO Diversification & Overseas Foray
- Green chemistry push: Rossari is focusing on non-EO product categories including surfactants like Esters, Acrylic Polymers, other polymers based on different monomers, and Methyl Esters of vegetable oils. These are green chemistries with practically zero effluent, targeting applications in Agro, Home and Personal Care, oil and gas, pharma, and paints and coatings.
- No EO/non-EO revenue split available: Management stated it is practically impossible to provide a breakup of HPPC revenue between EO and non-EO chemistries, because formulations contain both.
- Southeast Asia formulation hub: The company is setting up an overseas formulation facility to serve as a strategic hub for Southeast Asian markets, with a modest initial CAPEX of ₹15-20 crore. The facility will start with formulation activities, and further CAPEX will be added as business grows and market acceptance is seen.
- Competitive set is global: In non-EO chemistries, Rossari competes with global majors like Dow, BASF, Lubrizol, INEOS, Nouryon, Sasol, and Stepan.
Sunil Chari: "The competition is all the global majors, who are the big global majors like Dow, BASF, Lubrizol, INEOS, Nouryon, Sasol, Stepan. So, these are the big ones who are global majors everywhere in the world."
Margin & Cost Structure
- Other expenses up on consumer business: Other expenses rose ~₹12 crore YoY, with almost 50% of the increase attributable to the institutional business. Manpower additions in this vertical will be substantially lower this year after adding nearly 100 people last year.
- Pricing caution persists: Management remains cautious on pricing, noting that some raw material prices have come down and expecting that some of that benefit will have to be passed on in coming quarters.
- Employee cost largely done: With the employee cost base now largely set, operating leverage is expected to be the primary margin driver going forward.
Ketan Sablok: "Yes, it should grow, but we are still being a little cautious because pricing is still a challenge for us. Some of the raw material prices have come down, and we expect that some of that we will have to give up in the coming quarters."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Lost export fulfillment | Missed Q1 export orders to be dispatched | Q2 FY26 |
| Annual revenue & EBITDA growth | Mid-double-digit, 14-15% growth on both top line and EBITDA | FY26 (annual) |
| B2C/institutional breakeven | Losses to reduce substantially; possible breakeven if next 2 quarters go well; definite breakeven by next year | By FY27 at EBITDA level |
| Capacity-driven margin expansion | 3x-4x asset turnover from new facilities, driving operating leverage and margin expansion | From FY27 onwards |
| Reliance enhanced EO availability | Reliance capacity expected on stream | Sep-Oct 2026 (per Reliance indication) |
| Optimal capacity utilization | Good utilization of expanded capacity | FY28, with 3-4 years to 100% |
| Overseas facility CAPEX | Initial ₹15-20 crore; further expansion contingent on market acceptance | Starting now; expansion timeline uncommitted |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue from operations | ₹543.7 crore, up 11.0% YoY |
| Volume growth | 11% YoY |
| EBITDA | ₹67.9 crore, up 4.6% YoY |
| EBITDA margin | 12.5%, compared to 13.3% in Q1 FY25 |
| EBITDA (excl. institutional and B2C) | ₹75 crore, up 12% YoY, adjusted margin about 16% |
| Institutional and B2C business loss | ~₹7 crore in Q1 |
| Institutional and B2C business FY25 revenue | ₹299 crore |
| Exports | ₹139 crore in Q1, expected 27%-28% of overall turnover on annualized basis |
| Core business QoQ revenue change | Down by ₹25 – ₹30 crore compared to Q4 FY25 |
| Production stoppage | 10-12 days intermittently due to CAPEX-related hot work |
| Expected annual revenue and EBITDA growth | 14%-15% (mid-double-digit) |
| Overseas formulation facility CAPEX | ₹15 crore – ₹20 crore |
| Institutional business gross margins | 28% to 30% |
| Other expenses YoY increase | ~₹12 crore, ~50% from Institutional Business |